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Somatic chromosomal deletions in cancer are thought to indicate the location of tumour suppressor genes, by which a complete loss of gene function occurs through biallelic deletion, point mutation or epigenetic silencing, thus fulfilling Knudson's two-hit hypothesis 1 . In many recurrent deletions, however, such biallelic inactivation has not been found. One prominent example is the 5q 2 syndrome, a subtype of myelodysplastic syndrome characterized by a defect in erythroid differentiation 2 . Here we describe an RNAmediated interference (RNAi)-based approach to discovery of the 5q 2 disease gene. We found that partial loss of function of the ribosomal subunit protein RPS14 phenocopies the disease in normal haematopoietic progenitor cells, and also that forced expression of RPS14 rescues the disease phenotype in patient-derived bone marrow cells. In addition, we identified a block in the processing of pre-ribosomal RNA in RPS14-deficient cells that is functionally equivalent to the defect in Diamond-Blackfan anaemia, linking the molecular pathophysiology of the 5q 2 syndrome to a congenital syndrome causing bone marrow failure. These results indicate that the 5q 2 syndrome is caused by a defect in ribosomal protein function and suggest that RNAi screening is an effective strategy for identifying causal haploinsufficiency disease genes.
The 5q 2 syndrome was reported in 1974 as the first chromosomal deletion in cancer associated with a distinct clinical phenotype 2 . Patients have a severe macrocytic anaemia, normal or elevated platelet counts, normal or reduced neutrophil counts, erythroid hypoplasia in the bone marrow, and hypolobated micromegakaryocytes 3 . These patients also have a propensity to progress to acute myeloid leukaemia (AML), although more slowly than other forms of myelodysplastic syndrome (MDS) 4 . A main cause of morbidity and mortality for these patients is the erythroid defect, which often requires continuing transfusions of red blood cells resulting in iron overload and subsequent organ dysfunction 4 . The 5q 2 syndrome is also unique because this subtype of MDS shows a remarkable response to treatment with the thalidomide analogue lenalidomide, although the mechanism of action of lenalidomide remains unknown 5 . Over the past 30 years, physical mapping methods have been used to narrow the region of recurrent somatic deletion on 5q to a 1.5-megabase common deleted region (CDR) containing 40 genes 6 . No patients with the 5q 2 syndrome have been reported to have biallelic deletions within the CDR, and no point mutations have been reported in the remaining allele of any of the 40 genes in the region. This observation led us to speculate that the 5q 2 syndrome may be caused by haploinsufficiency, suggesting that an alternative approach would be required to identify the gene responsible. We therefore examined whether the principal hallmarks of the disease (an erythroid maturation block with preservation of megakaryocyte differentiation) could be recapitulated experimentally with short hairpin RNAs (shRNAs) targeting each of the genes within the CDR.
We designed multiple lentivirally expressed shRNAs for each of the candidate genes, to control for possible off-target effects of any individual shRNA. The shRNAs were introduced into normal CD34 1 human haematopoietic progenitor cells, and the cells were induced to differentiate for 10 days along the erythroid and megakaryocytic lineages. The effect of each shRNA was assessed by fluorescenceactivated cell sorting (FACS) analysis with the use of erythroidspecific and megakaryocyte-specific cell surface markers. The shRNAs targeting one gene, RPS14, recapitulated the 5q 2 syndrome phenotype: a severe decrease in the production of erythroid cells with relative preservation of megakaryocytic cells (Fig. 1) . Furthermore, using the sequential expression of CD71 and glycophorin A during erythroid differentiation ( Supplementary Fig. 1 ), we found that shRNAs targeting RPS14 blocked the production of terminally differentiated erythroid cells, which is also consistent with the 5q 2 syndrome disease phenotype ( Supplementary Fig. 2) . In a statistical analysis that grouped all shRNAs targeting each gene into a single set, RPS14 was the only gene that significantly altered differentiation ( Supplementary Fig. 3 ). On the basis of these results, we focused our attention on RPS14 as a candidate disease gene.
We first confirmed that all five RPS14 shRNAs that scored in the screen in fact knocked down RPS14 expression, and that the level of protein expression was of the order of half of the luciferase control cells, which is consistent with a model of RPS14 haploinsufficiency (Fig. 2a) . Each of the RPS14 shRNAs decreased erythroid differentiation relative to megakaryocytic differentiation (Fig. 2b ) and also caused a mild defect in erythroid versus myeloid differentiation (Fig. 2c) , precisely as seen in patients with the clinical syndrome. RPS14 knockdown also caused an increase in the ratio of immatureto-mature erythroid cells (Fig. 2d) , as well as increased apoptosis of differentiating erythroid cells (Fig. 2e) , which is consistent with the well-described apoptotic phenotype of MDS 7 . Given the possibility that multiple genes in the CDR might act in collaboration 8 , we tested whether other effective shRNAs might increase the effect of RPS14 knockdown. None of the combinations was more effective than RPS14 shRNAs alone, suggesting that RPS14 is the critical gene in the region that explains the haematopoietic differentiation defect associated with 5q 2 syndrome ( Supplementary Fig. 4 ). To confirm that RPS14 deficiency truly affects the erythroid differentiation programme (rather than simply modulating the expression of specific FACS markers), we performed genome-wide expression profiling of cells infected with control or RPS14 shRNAs.
We used gene set enrichment analysis (GSEA) 9 to assess the effect of RPS14 knockdown on experimentally derived signatures of erythroid and megakaryocytic differentiation (Fig. 2f) . As expected, the gene expression pattern of RPS14 knockdown showed a significant abrogation of the erythroid differentiation signature (P , 0.001; Fig. 2g ), in the setting of increased signature of neutrophil and platelet differentiation (P , 0.001 for both; Fig. 2h, i ). In addition, RPS14 shRNAs induced a signature of sensitivity to lenalidomide, the only drug approved by the Food and Drug Administration specifically for MDS patients with 5q deletions 5 ( Supplementary Fig. 5 ). The RPS14 shRNAs knocked down RPS14 expression by an average of about 60% in these samples, which is consistent with haploinsufficiency as the cause of these phenotypes. To exclude further the possibility of biallelic inactivation of RPS14, we sequenced the RPS14 gene in 32 MDS patient samples and subjected a subset of these samples to high-density singlenucleotide-polymorphism-based copy number analysis and gene expression profiling. In no case did we detect RPS14 point mutations, cryptic biallelic deletions or loss of expression (for example, by aberrant methylation; see Supplementary Fig. 6 ). Taken together, these experiments show that partial loss of function of RPS14 recapitulates the phenotype of the 5q 2 syndrome. RPS14 is a component of the 40S ribosomal subunit, but the function of RPS14 in human cells has not been defined. To determine the effect of partial loss of function of RPS14 on pre-rRNA processing, we performed northern blotting of rRNA transcripts and sucrosegradient analysis of intact polysomes. Decreased expression of RPS14 resulted in an accumulation of the 30S pre-rRNA species with a concomitant decrease in levels of 18S/18SE rRNA levels ( Fig. 3a, b) , which is consistent with reports for Saccharomyces cerevisiae that RPS14 is required for the processing of 18S pre-rRNA 10 . Specifically, a fourfold to ninefold increase in the 30S/18SE ratio was observed in cells expressing RPS14 shRNAs. In addition, RPS14 knockdown abrogated formation of the 40S subunit ( Fig. 3c and Supplementary Fig. 7 ). The increased 30S/18SE ratio in RPS14-deficient cells was not simply a consequence of cell death: the ribosomal processing defect occurred before the onset of significant apoptosis, and pharmacologically induced apoptosis failed to generate the characteristic 30S/18S defect ( Supplementary Figs 8 and 9 ).
These results indicate that the block in pre-rRNA processing is a specific consequence of RPS14 deficiency.
An increase in the 30S/18SE ratio was observed in bone marrow cells from patients with 5q
2 syndrome in comparison with those from normal marrow (Fig. 3d) , suggesting that a pre-rRNA processing defect does indeed occur in cells from patients. We note that the samples from patients contain a mixture of normal and 5q 2 disease cells, probably explaining why the 30S/18SE ratio is less perturbed than that seen in the experimental setting. The essential nature of RPS14 in ribosome biogenesis also probably explains why a complete loss of RPS14 (for example, through biallelic deletions) is never seen in cells from patients with 5q 2 syndrome. Complete loss of RPS14 is probably incompatible with cell survival, as it is in yeast 10 . To establish further that RPS14 deficiency accounts for the haematopoietic defect characteristic of 5q 2 syndrome, we attempted to rescue the erythroid differentiation defect in patient-derived bone marrow cells by using an RPS14 expression construct. CD34
1 cells from viably frozen bone marrow mononuclear cells obtained from MDS patients with and without 5q deletions (Supplementary Table  4 ) were induced to undergo differentiation in vitro. FACS analysis showed that in comparison with control, lentiviral expression of RPS14 increased erythroid differentiation in patients with the 5q 2 syndrome but failed to do so in patients lacking 5q deletions (P 5 0.004 for erythroid relative to megakaryocytic differentiation; P 5 0.0003 for erythroid relative to myeloid; Fig. 4 and Supplementary Fig. 10 ). Furthermore, gene expression profiling coupled with GSEA showed that ectopic expression of RPS14 induced the gene expression signature of erythroid differentiation in 5q 2 syndrome patient samples (P , 0.001; Supplementary Fig. 11 ). These data demonstrate that overexpression of RPS14 rescues the erythroid differentiation defect seen in patients with 5q
2 syndrome, and establishes RPS14 as the likely disease-causing gene.
Loss of function of a ribosomal protein might at first seem like an unlikely explanation for a disease with such a distinct haematopoietic phenotype. However, germline heterozygous mutations for two other ribosomal proteins-RPS19 and RPS24-have recently been described in the congenital disorder known as Diamond-Blackfan anaemia 11, 12 . The phenotype of Diamond-Blackfan anaemia is strikingly similar to the 5q 2 syndrome: patients have a severe anaemia, a b Luc  GATA1  TNIP1  CSF1R  GLRA1  SH3TC2  SYNPO  PCYOX1L  AFAPIL1  CDX1  MYOZ3  FLJ41603  ANXA6  ZNF300  CD74  SPARC  PPARGC1B  PDGFRB  PDE6A  IL17B  DCTN4  CSNK1A1  ATOX1  SLC36A2  G3BP  DKFZP434C171  SLC36A3  GPX3  ABLIM3  TIGD6  SLC26A2  GRPEL2  NDST1  NID67  CAMK2A  SLC36A1  SLC6A7  FAT2  TCOF1  GM2A  RBM22 macrocytosis, relative preservation of the platelet and neutrophil counts, erythroid hypoplasia in the bone marrow and an increased risk of leukaemia. Analogous to our results demonstrating RPS14 function in 18S pre-rRNA processing and 40S polysome formation, a similar requirement of RPS19 in ribosomal biogenesis has recently been shown 13 . Beyond Diamond-Blackfan anaemia, the genes implicated in other paediatric bone marrow failure syndromes, including Shwachman-Diamond syndrome, dyskeratosis congenita and cartilage-hair hypoplasia, are also involved in ribosomal biogenesis 14 . Our findings therefore establish a logical link between the 5q 2 syndrome, caused by the somatic deletion of one allele of RPS14, and congenital bone marrow failure syndromes, caused by the heritable mutation of other ribosome-associated proteins. The erythroid specificity of acquired or inherited defects in RPS14, RPS19 or RPS24 expression is noteworthy. Although these ribosomal proteins and the ribosomal subunits they constitute are thought to be ubiquitous, the erythroid lineage is under particularly high biosynthetic demand. Erythroid progenitor cells proliferate extraordinarily rapidly (yielding 2 3 10 11 new red cells per day in an adult human) 15 , and contain extremely high concentrations of globin proteins-all resulting in a high demand for ribosomal biogenesis. Furthermore, erythroid cells must balance the production of haem and the translation of globin proteins precisely; otherwise the cells undergo apoptosis 16 . It is therefore possible that partial loss of ribosomal function in other lineages may not result in an obvious phenotype. We also note that in an unbiased screen in zebrafish for genes that cause tumours after the loss of a single allele, 92% of the tumour-prone fish lines had hemizygous mutations in genes encoding ribosomal proteins 17 . These observations suggest that loss of function of RPS14 in the 5q 2 syndrome may explain not only the erythroid differentiation defect seen in affected patients but also their propensity to progress to acute leukaemia. The mechanism by which ribosomal dysfunction is tumorigenic in fish has yet to be determined. 0.8
RPS14 shRNA 1 cells. The ratios of cells from the erythroid and megakaryocytic lineages, indicated on the y axis, were assessed by flow cytometry with antibodies against GlyA and CD41, respectively. c-e, In addition, RPS14 shRNAs decrease erythroid relative to myeloid differentiation, assessed with antibodies against GlyA and CD11b (c), block terminal erythroid differentiation, assessed with antibodies against GlyA and CD71 (d), and increase apoptosis, assessed by annexin V expression (e). In b-e the effect of RPS14 shRNAs, in contrast with the Luc shRNA, was statistically significant (P , 0.05 by Student's two-tailed t-test, mean and s.e.m. shown (n 5 3)). f, Multiple shRNAs targeting RPS14 also alter the transcriptional programs of lineage-specific differentiation. The top 100 marker genes that are differentially expressed between cells expressing control versus RPS14 shRNAs, ranked by signal to noise ratio 25 . RPS14 is at the top of the list of downregulated genes and is expressed at about 40% of the normal level. Error bars indicate s.e.m. g-i, RPS14 shRNAs significantly decrease the expression of an erythroid gene expression signature 26 (g) and increase the expression of neutrophil 27 (h) and platelet 28 (i) signatures, as assessed by GSEA. Genes are ranked by signal/noise ratio according to their differential expression between cells expressing RPS14 and control shRNAs. Genes in the lineage-specific gene sets are marked with vertical bars, and the enrichment score is shown in green. 
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Figure 3 | RPS14 is required for 18S pre-rRNA processing and 40S ribosomal subunit formation. a, A simplified diagram of pre-rRNA processing. b, A defect in the 59 processing of 18S pre-rRNA is evident from northern blots using RNA from TF-1 cells expressing control or RPS14 shRNAs, with an accumulation of 30S rRNA and a deficiency of 21S and 18SE pre-rRNAs and mature 18S rRNA. The northern blot probes are shown in red. c, Polysome profiles from TF-1 cells show that decreased expression of RPS14 results in a 40S subunit deficiency. d, The 30S/18SE pre-rRNA ratio is also increased in RNA from bone marrow mononuclear cells from MDS patients with 5q
2 syndrome (n 5 4) compared with that from MDS patients without 5q deletions (n 5 5), as measured by quantification of northern blots (P 5 0.06). Error bars indicate s.e.m.
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The experiments described here establish RPS14 as a causal gene for the 5q 2 syndrome. However, it is conceivable that other genes (on 5q or elsewhere) collaborate with RPS14 to cause the disease phenotype. We speculate that whereas RPS14 loss of function may be sufficient for the erythroid differentiation defect, additional mutations may be required for RPS14-deficient cells to reach clonal dominance and to progress to malignant transformation to AML. In that regard, the 5q 2 syndrome region on chromosome 5 should be distinguished from a more centromeric locus on 5q that has been associated with therapy-related and aggressive subtypes of MDS as well as AML, and for which two candidate genes have been recently reported [18] [19] [20] . In most patients a large portion of 5q is deleted, encompassing both critical regions, so it is possible that the loss of both RPS14 and a second collaborating gene is achieved in a single genetic event.
Acquired deletions are a hallmark of cancer and pre-cancerous states. In general, such deletions flag the existence of a tumour suppressor gene conforming to Knudson's two-hit hypothesis, in which one allele is often deleted and the other allele is inactivated by deletion, mutation or epigenetic modification. However, in multiple tumour types (for example 1p deletions in neuroblastoma, 3p deletions in lung cancer, and 7q deletions in myeloid malignancies) the search for the key tumour suppressor gene has been elusive. A possible explanation for the failure to identify these classic tumour suppressor genes is that oncogenesis is caused by allelic insufficiency 21 . The recent discovery of monoallelic deletions or mutations in PAX5 in acute lymphoblastic leukaemia supports this hypothesis 22 . Our RNA interference-based discovery of the 5q 2 syndrome gene suggests that haploinsufficient disease genes can be identified with this approach. It is possible that the systematic application of RNAi might similarly identify the genes responsible for other diseases caused by allelic insufficiency.
METHODS SUMMARY
Culture of haematopoietic progenitor cells. Primary normal human bone marrow or umbilical cord blood CD34
1 cells were differentiated in vitro with a two-phase liquid culture system using combinations of cytokines supporting erythroid, myeloid and megakaryocytic differentiation 23 . Viable cells from bone marrow aspirates from patients with MDS were collected under a protocol approved by the institutional review board at Massachusetts General Hospital. Lentiviral vectors. Multiple shRNA lentiviruses targeting each gene in the CDR for the 5q 2 syndrome were produced as described previously 24 . The target sequence of each shRNA is listed in Supplementary Table 2 . Flow cytometry. Haematopoietic differentiation was assessed by flow cytometry with antibodies specific for terminally differentiated erythroid cells (GlyA), immature erythroid cells (CD71), megakaryocytes (CD41) and myeloid cells (CD11b). Microarrays with GSEA. Linear amplification of RNA was performed with the Ovation kit (Nugen) and labelled cDNA was applied to oligonucleotide microarrays (Affymetrix). GSEA was performed as described previously 9 . Microarray experiments and gene sets are listed in Supplementary Tables 3 and 4 , respectively, and the data are available at GEO under accession number GSE9487. Ribosomal RNA processing and polysome profiles. The effect of RPS14 knockdown on pre-rRNA processing was performed by northern blot analysis. Polysome fractionation on a sucrose gradient and spectrophotometric detection were performed as described previously 13 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 2 syndrome (a, c; red) and MDS patients without 5q deletions (b, d; blue) were infected with a lentivirus expressing the RPS14 complementary DNA or an empty vector. In patients with 5q deletions, RPS14 overexpression increased erythroid relative to megakaryocytic differentiation (a, b) and erythroid relative to myeloid differentiation (c, d) shown normalized to the empty-vector control. Means and s.e.m. for three independent experiments are shown. e-h, Representative flow cytometry plots for patient 1. In comparison with the empty vector control (e, g), overexpression of RPS14 (f, h) results in an increase in GlyA expression and a decrease in CD41 (e, f) and CD11b (g, h).
